SERUM OSTEOPROTEGERIN FOR EARLY IDENTIFICATION OF CAD IN TYPE 2 DM PATIENTS

Abstract

Background:

Osteoprotegerin (OPG) is a well-known protein, it can reduce the osteoclast production and it also be used to identify people with CAD. The aim of this study was to investigate OPG levels, CIMT, and CAC measures in diabetic participants, as well as examine the link between blood OPG levels and early atherosclerosis such as CIMT, CAC, and GLS in patients with type 2 DM.

Method:

The study included 160 type 2 DM patients. All study were investigated GLS and venous blood specimens were collected to determine OPG. Serum OPG levels was determined using an ELISA. FPG, PPBS, and HbA1c values were assessed. CIMT were measured with B-mode ultrasonography, CAC were measured with CT.

Results:

The OPG levels were substantially higher in FBS >126 mg/dl group (1.64 ng/ml) compared to the FBS ≤126 mg/dl group (1.00 ng/ml). Mean OPG levels were higher in the PPBS ≥200 mg/dl group (1.47 ng /ml) compared to the PPBS <200 mg/dl group (0.93 ng /ml). The mean OPG level were substantially higher in abnormal CIMT (1.74 ng/ml) when compared to the normal CIMT (0.92 ng /ml). Mean OPG level was statistically significant in abnormal GLS (1.91 ng/ml) compared to the normal GLS group (1.15 ng/ml). Serum OPG levels also demonstrated a significant increase with disease severity. Mean levels ranged from 0.67 ng/ml in the "normal" group to 3.93ng/ml in the "severe" group, with a highly significant difference (F = 41.203, p= 0.000).

Conclusion:

Our study demonstrates the serum OPG levels are substantially associated with CAD severity, highlighting their potential as early biomarkers for CAD. This biomarker could complement existing diagnostic tools, allowing for earlier detection and better risk stratification in CAD patients.